Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$1.09M$1.09M+548.8% vs Q2 2020 Net Income-$17.96M-$17.96MN/M vs Q2 2020 EPS Diluted-$2.21-$2.21N/M vs Q2 2020 Operating Income-$17,998,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,685,000N/M Margins · derivedOperating margin-1651.2%+2142.9 pt vs Q2 2020
Net margin-1648.1%+2182.3 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end